BR0311883A - Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do paciente - Google Patents
Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do pacienteInfo
- Publication number
- BR0311883A BR0311883A BR0311883-5A BR0311883A BR0311883A BR 0311883 A BR0311883 A BR 0311883A BR 0311883 A BR0311883 A BR 0311883A BR 0311883 A BR0311883 A BR 0311883A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- adenosine
- prophylaxis
- tissue
- patient
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title abstract 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 title abstract 6
- 229960005305 adenosine Drugs 0.000 title abstract 6
- 238000011282 treatment Methods 0.000 title abstract 5
- 208000006673 asthma Diseases 0.000 title abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000035945 sensitivity Effects 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical class C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000010902 jet-milling Methods 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000006199 nebulizer Substances 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38924202P | 2002-06-17 | 2002-06-17 | |
| US47798703P | 2003-06-11 | 2003-06-11 | |
| PCT/US2003/018944 WO2004012653A2 (en) | 2002-06-17 | 2003-06-17 | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311883A true BR0311883A (pt) | 2005-04-05 |
Family
ID=29740120
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311883-5A BR0311883A (pt) | 2002-06-17 | 2003-06-17 | Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do paciente |
| BR0311885-1A BR0311885A (pt) | 2002-06-17 | 2003-06-17 | Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311885-1A BR0311885A (pt) | 2002-06-17 | 2003-06-17 | Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090087389A1 (enExample) |
| EP (2) | EP1553954A4 (enExample) |
| JP (2) | JP2005537296A (enExample) |
| KR (2) | KR101005819B1 (enExample) |
| CN (2) | CN100540007C (enExample) |
| AU (2) | AU2003269889B2 (enExample) |
| BR (2) | BR0311883A (enExample) |
| CA (2) | CA2491846A1 (enExample) |
| IL (2) | IL165378A0 (enExample) |
| MX (2) | MXPA04012720A (enExample) |
| WO (2) | WO2004012653A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050057086A (ko) * | 2002-08-28 | 2005-06-16 | 홀리스-에덴 파마슈티칼즈, 인코포레이티드 | 치료적 처치 방법 |
| EP1638549A4 (en) | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| US7858607B2 (en) | 2003-03-14 | 2010-12-28 | Mamchur Stephen A | System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer |
| CA2611907A1 (en) * | 2005-06-17 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Mrp iv inhibitors for the treatment of respiratory diseases |
| GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
| MX2008012794A (es) * | 2006-04-03 | 2008-10-15 | Teva Pharma | Microparticulas de farmacos. |
| EP2170270B1 (en) * | 2007-06-05 | 2016-01-13 | Paka Pulmonary Pharmaceuticals, Inc. | Compositions for delivering medicaments into the lungs, uses thereof |
| CA2703475A1 (en) | 2007-10-25 | 2009-04-30 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| EP2358379B1 (en) * | 2008-10-24 | 2015-12-16 | Cempra Pharmaceuticals, Inc. | Biodefenses using triazole-containing macrolides |
| WO2010068754A2 (en) | 2008-12-10 | 2010-06-17 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| ES2608285T3 (es) | 2009-09-10 | 2017-04-07 | Cempra Pharmaceuticals, Inc. | Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC |
| KR101945324B1 (ko) | 2010-05-20 | 2019-02-07 | 셈프라 파마슈티컬스, 인크. | 매크로라이드들 및 케톨라이드들과 이의 중간체들을 제조하는 공정들 |
| US9815863B2 (en) | 2010-09-10 | 2017-11-14 | Cempra Pharmaceuticals, Inc. | Hydrogen bond forming fluoro ketolides for treating diseases |
| KR20140139083A (ko) | 2012-03-27 | 2014-12-04 | 셈프라 파마슈티컬스, 인크. | 마크롤라이드계 항생제를 투여하기 위한 비경구 제제 |
| RU2015138796A (ru) * | 2013-03-14 | 2017-04-19 | Семпра Фармасьютикалс, Инк. | Способы и составы для лечения респираторных заболеваний |
| JP6675973B2 (ja) | 2013-03-15 | 2020-04-08 | センプラ ファーマシューティカルズ，インコーポレイテッド | マクロライド抗菌薬を調製するための集束的な方法 |
| US10130713B2 (en) * | 2013-04-19 | 2018-11-20 | The Methodist Hospital | Cocrystalline DHEA formulations |
| WO2025076250A1 (en) * | 2023-10-04 | 2025-04-10 | The Trustees Of Indiana University | Slow-release compositions and methods for inflammatory airway obstruction |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3943987A (en) * | 1974-10-17 | 1976-03-16 | Rossi Thomas J | Reclosable air-tight containers with evacuation means |
| US4379842A (en) * | 1980-02-13 | 1983-04-12 | Hoffmann-La Roche Inc. | Process for the manufacture of 1α-hydroxydehydroepiandrosterone |
| US4393066A (en) * | 1981-06-05 | 1983-07-12 | Garrett David M | Method for treatment of herpetic lesions |
| US4499064A (en) * | 1982-06-03 | 1985-02-12 | Clayton Foundation For Research | Assessment of nutritional status of individuals |
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
| US4575498A (en) * | 1983-07-21 | 1986-03-11 | Duke University | Method for restoring depleted purine nucleotide pools |
| US4628052A (en) * | 1985-05-28 | 1986-12-09 | Peat Raymond F | Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities |
| JPS63104924A (ja) * | 1986-10-20 | 1988-05-10 | Kanebo Ltd | 膣坐剤 |
| NL194728C (nl) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan. |
| CH673459A5 (enExample) * | 1987-05-15 | 1990-03-15 | Eprova Ag | |
| ES2043897T3 (es) * | 1988-01-28 | 1994-01-01 | Koeltringer Peter | Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas. |
| FR2631828B1 (fr) * | 1988-05-27 | 1994-05-20 | Spiral Recherche Developpement | Utilisation d'une substance folinique en tant qu'agent antiagregant plaquettaire |
| US4931441A (en) * | 1988-11-09 | 1990-06-05 | Luitpold Pharmaceuticals, Inc. | Stabilized aqueous leucovorin calcium compositions |
| US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
| US5077284A (en) * | 1988-12-30 | 1991-12-31 | Loria Roger M | Use of dehydroepiandrosterone to improve immune response |
| US5407684A (en) * | 1988-12-30 | 1995-04-18 | Virginia Commonwealth University | Use of DHEA as a medicinal |
| IT1229517B (it) * | 1989-01-31 | 1991-09-03 | Bioresearch Spa | Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| NL8901432A (nl) * | 1989-06-06 | 1991-01-02 | Pharmachemie Bv | Bij koelkasttemperatuur stabiele waterige folinaatoplossing, alsmede werkwijze ter bereiding daarvan. |
| US4985443A (en) * | 1989-08-04 | 1991-01-15 | Montes Leopoldo F | Method and composition for treating vitiligo |
| US5173488A (en) * | 1989-08-21 | 1992-12-22 | American Cyanamid Company | Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method |
| US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| US5162198A (en) * | 1991-02-08 | 1992-11-10 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation |
| US5110810A (en) * | 1991-02-08 | 1992-05-05 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation |
| US5266312A (en) * | 1992-01-07 | 1993-11-30 | National Jewis Center For Immunology And Respiratory Medicine | Method for treating a steroid resistant condition via administration of gamma interferon |
| EP0627921B1 (en) * | 1992-02-24 | 2000-05-31 | East Carolina University | Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
| US6093706A (en) * | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
| US5686438A (en) * | 1993-03-09 | 1997-11-11 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| ES2261836T3 (es) * | 1993-01-19 | 2006-11-16 | Endorecherche Inc. | Usos terapeuticos de dehidroepiandrosterona para tratamiento de libido disminuida y osteoporosis. |
| US5635496A (en) * | 1993-03-09 | 1997-06-03 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| KR960700728A (ko) * | 1993-03-09 | 1996-02-24 | 토마스 메이져 | 진행성 조직 괴사, 재관류 손상, 세균 전이 및 성인 호흡 장애 증후군의 예방 방법(Methods for Preventing Progressive Tissue Necrosis, Reperfusion Injury, Bacterial Translocation and Adult Respiratory Distress Syndrome) |
| US5811418A (en) * | 1993-03-09 | 1998-09-22 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5407927A (en) * | 1993-04-16 | 1995-04-18 | The Regents Of The University Of California | Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone |
| CA2204902A1 (en) * | 1994-11-30 | 1996-06-06 | Fred I. Chasalow | Phosphocholine drug derivatives |
| US20020032160A1 (en) * | 1995-02-24 | 2002-03-14 | Nyce Jonathan W. | Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels |
| US5660835A (en) * | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
| US5859000A (en) * | 1995-06-07 | 1999-01-12 | University Of Utah Research Foundation | Method for reducing mast cell mediated allergic reactions |
| US5767278A (en) * | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| CA2632790A1 (en) * | 1996-07-22 | 1998-01-29 | Renovo Limited | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| US5861391A (en) * | 1997-01-29 | 1999-01-19 | Research Development Foundation | Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease |
| US20030013772A1 (en) * | 2000-02-23 | 2003-01-16 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
| AU763307B2 (en) * | 1998-02-04 | 2003-07-17 | Charlotte-Mecklenburg Hospital Authority | Androsterone derivatives for inhibiting DNA binding of AP-1 and airway smooth muscle proliferation |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| HU226164B1 (en) * | 1998-11-13 | 2008-05-28 | Jagotec Ag | Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation |
| AU779138B2 (en) * | 1999-03-18 | 2005-01-06 | Genelabs Technologies, Inc. | DHEA composition and method |
| US6428769B1 (en) * | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| US7381713B2 (en) * | 2000-12-04 | 2008-06-03 | Sioan-Kettering Institute For Cancer Research | Treatment of cancer by reduction of intracellular energy and pyrimidines |
| AU2002303425A1 (en) * | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| US20030216329A1 (en) * | 2001-04-24 | 2003-11-20 | Robinson Cynthia B. | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
| US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
| US7405207B2 (en) * | 2002-06-17 | 2008-07-29 | Epigenesis Pharmaceuticals, Inc. | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
-
2003
- 2003-06-17 IL IL16537803A patent/IL165378A0/xx unknown
- 2003-06-17 BR BR0311883-5A patent/BR0311883A/pt not_active IP Right Cessation
- 2003-06-17 CN CNB038136910A patent/CN100540007C/zh not_active Expired - Fee Related
- 2003-06-17 CA CA002491846A patent/CA2491846A1/en not_active Abandoned
- 2003-06-17 KR KR1020047020590A patent/KR101005819B1/ko not_active Expired - Fee Related
- 2003-06-17 MX MXPA04012720A patent/MXPA04012720A/es active IP Right Grant
- 2003-06-17 AU AU2003269889A patent/AU2003269889B2/en not_active Ceased
- 2003-06-17 KR KR1020047020469A patent/KR20060011784A/ko not_active Abandoned
- 2003-06-17 CN CNA038136813A patent/CN1681520A/zh active Pending
- 2003-06-17 WO PCT/US2003/018944 patent/WO2004012653A2/en not_active Ceased
- 2003-06-17 MX MXPA04012728A patent/MXPA04012728A/es not_active Application Discontinuation
- 2003-06-17 JP JP2004525996A patent/JP2005537296A/ja active Pending
- 2003-06-17 EP EP03751776A patent/EP1553954A4/en not_active Withdrawn
- 2003-06-17 BR BR0311885-1A patent/BR0311885A/pt not_active IP Right Cessation
- 2003-06-17 WO PCT/US2003/018945 patent/WO2003105775A2/en not_active Ceased
- 2003-06-17 EP EP03766816A patent/EP1513509A4/en not_active Withdrawn
- 2003-06-17 IL IL16529103A patent/IL165291A0/xx unknown
- 2003-06-17 AU AU2003276836A patent/AU2003276836B2/en not_active Ceased
- 2003-06-17 CA CA002489124A patent/CA2489124A1/en not_active Abandoned
- 2003-06-17 JP JP2004512683A patent/JP2005530820A/ja active Pending
-
2008
- 2008-09-25 US US12/238,403 patent/US20090087389A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003269889A1 (en) | 2003-12-31 |
| CA2491846A1 (en) | 2003-12-24 |
| JP2005537296A (ja) | 2005-12-08 |
| EP1553954A2 (en) | 2005-07-20 |
| BR0311885A (pt) | 2005-04-05 |
| US20090087389A1 (en) | 2009-04-02 |
| MXPA04012728A (es) | 2006-02-02 |
| KR20060011784A (ko) | 2006-02-03 |
| WO2003105775A3 (en) | 2004-04-08 |
| WO2004012653A2 (en) | 2004-02-12 |
| EP1513509A4 (en) | 2009-05-27 |
| JP2005530820A (ja) | 2005-10-13 |
| CN1658884A (zh) | 2005-08-24 |
| IL165291A0 (en) | 2005-12-18 |
| WO2003105775A2 (en) | 2003-12-24 |
| MXPA04012720A (es) | 2007-03-23 |
| AU2003269889B2 (en) | 2007-04-19 |
| KR101005819B1 (ko) | 2011-01-05 |
| EP1553954A4 (en) | 2009-12-23 |
| AU2003276836B2 (en) | 2007-05-10 |
| IL165378A0 (en) | 2006-01-15 |
| EP1513509A2 (en) | 2005-03-16 |
| CN100540007C (zh) | 2009-09-16 |
| KR20050037515A (ko) | 2005-04-22 |
| AU2003276836A1 (en) | 2004-02-23 |
| WO2004012653A3 (en) | 2004-07-08 |
| CN1681520A (zh) | 2005-10-12 |
| CA2489124A1 (en) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0311883A (pt) | Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do paciente | |
| Iwabuchi et al. | Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases | |
| Klimke et al. | Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection | |
| Lavorini et al. | Dilemmas, confusion, and misconceptions related to small airways directed therapy | |
| Schuh et al. | Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma | |
| Madney et al. | The influence of changing interfaces on aerosol delivery within high flow oxygen setting in adults: an in-vitro study | |
| Zhang et al. | The use of a modified, oscillating positive expiratory pressure device reduced fever and length of hospital stay in patients after thoracic and upper abdominal surgery: a randomised trial | |
| Gryn et al. | The toxicity of daily inhaled amphotericin B | |
| Gaston et al. | Buffering airway acid decreases exhaled nitric oxide in asthma | |
| Rodgers et al. | The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis | |
| Martinez et al. | Vertebral Aspergillus osteomyelitis and acute diskitis in patients with chronic obstructive pulmonary disease | |
| Eliçora et al. | Tracheobronchial tooth and dental prosthesis aspirations: 15 cases | |
| Peruzzi et al. | Bronchial hygiene therapy | |
| US11160814B1 (en) | Methods of treatment for disease from coronavirus exposure | |
| Gervais et al. | Bronchodilatation with a metered-dose inhaler plus an extension, using tidal breathing vs jet nebulization | |
| Cochrane et al. | Home nebulisers for airflow limitation | |
| Lanz et al. | The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast | |
| Lenaeus et al. | Primary care of the patient with asthma | |
| Ariel et al. | Rational use of inhaled corticosteroids for the treatment of COPD: a plain language summary | |
| Kumar et al. | Study of surgical fixation of extra-articular distal third humerus fractures with a posterolateral locking compression plate | |
| Torres-Larrosa et al. | Nasal leprosy: impact of multitherapy in the morphology and physiology of the nose | |
| Haubitz et al. | Exhaled nitric oxide in patients with Wegener's granulomatosis | |
| Peruzzi et al. | Respiratory care | |
| Kim et al. | Artificial external glottic device for passive lung insufflation | |
| Sankarganesh et al. | Lung Expansion Therapy for the Potential Populations: A Literature Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 31/704, A61K 31/66, A61K 31/57, A61K 31/56,A61P 11/00 Ipc: A61K 31/704 (2011.01), A61K 31/66 (2011.01), A61K |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012. |